Imagine being 23, living with a genetic condition called neurofibromatosis type 1 (NF1), and then facing a rare and aggressive cancer called a Malignant Triton Tumor. That was the reality for one young woman. After surgeons removed a tumor from her chest, it returned in her chest cavity just two months later. Her medical team then tried a combination of chemotherapy, targeted therapy, and a newer type of immunotherapy. For her, this approach led to a stabilization of the disease. Researchers also performed a detailed genetic analysis on her tumor cells. This showed the cancer was made up of many different types of cells, highlighting its complex and varied nature. It's crucial to remember this is the story of just one person. The treatment that helped her is not a proven regimen, and the genetic findings, while fascinating, are specific to her tumor. This case report is a detailed snapshot that underscores how challenging these tumors can be and points to areas for future research, but it doesn't offer general answers yet.
Photo by Dmytro Vynohradov / Unsplash
What happens when a rare cancer returns? One young woman's story offers a clue.
Plain Language Summary
What this means for you:
One woman's rare cancer stabilized with a complex treatment; her case is a starting point, not a blueprint. What this means for you:
One woman's rare cancer stabilized with a complex treatment; her case is a starting point, not a blueprint. View Original Abstract ↓
BackgroundMalignant Triton Tumor (MTT) is a rare, highly aggressive peripheral nerve sheath tumor characterized by rhabdomyoblastic differentiation, seldom occurring primarily in the thoracic cavity. This report presents a rare case of MTT initially manifesting as chest pain, and reviews relevant literature to summarize its clinical features and therapeutic strategies.MethodsA 23-year-old woman experienced chest pain for ten days and her condition worsened within 3 days. The patient had a known history of neurofibromatosis type 1 (NF1) and exhibited classic café-au-lait spots on physical examination. Diagnosis was confirmed via chest CTA, PET-CT, bronchoscopy, ultrasound, and histopathology. After surgical resection, the tumor recurred rapidly, prompting multiple treatments including chemotherapy, targeted therapy, and combination immunotherapy.ResultsPathology after right lower lobectomy and chest wall resection confirmed MTT (S-100+/Desmin+/Myogenin+). Recurrence in the mediastinum was detected two months postoperatively. Disease stabilization was achieved using cadonilimab, apatinib, and ifosfamide/etoposide. Notably, the first application of single-cell RNA sequencing (scRNA-seq) in MTT, combined with the CopyKAT algorithm, distinguished malignant from non-malignant cells and revealed a heterogeneous tumor microenvironment composed of distinct functional cell populations, highlighting the tumor’s high degree of heterogeneity.ConclusionThis case underscores the importance of considering MTT in young NF1 patients presenting with intrathoracic masses. An individualized, multimodal treatment approach may extend survival. scRNA-seq provides valuable insights into the molecular landscape of MTT and hold promise for guiding precision therapy in the future.